Prolonged infusion of hemaxamethylene bisacetamide: A phase I and pharmacological study

E. K. Rowinsky, David S Ettinger, W. P. McGuire, D. A. Noe, L. B. Grochow, Ross C Donehower

Research output: Contribution to journalArticle

Abstract

Hexamethylene bisacetamide (HMBA, NSC 95580), a potent polar-planar differentiating agent in vitro, was studied in a phase I trial as a 10-day continuous infusion administered every 4 weeks. Since preclinical evidence had demonstrated that the duration of HMBA exposure was an important variable in the induction of differentiation, and HMBA steady-state concentrations (C(ss)) achieved during 5-day infusions were minimally effective at inducing in vitro differentiation, this study was conducted to evaluate the feasibility of maintaining HMBA C(ss) for 10 days similar to levels achieved and maintained for 5 days. Twelve patients received 17 evaluable courses at three dose levels, 12, 15.8, and 20 g/m2/day. Platelet toxicity limited further dose escalation. Mean nadir and percentage of decrement in platelet counts were 175,000/μl and 66%, and 43,500/μl and 83%, at 15.8 and 20 g/m2/day, respectively. In this 10-day study, the percentage of decrement of platelet counts was linearly related to mean HMBA C(ss) and to the area under the plasma concentration versus time curve (AUC). However, when combined platelet and pharmacological data from both 5- and 10-day studies were analyzed, it was apparent that the duration of HMBA exposure was an additional significant variable in predicting the magnitude of thrombocytopenia. Renal and metabolic toxicities that precluded dose escalation in previous 5-day trials of HMBA were mild and insignificant in this study. Mean HMBA C(ss) 0.65 ± 0.09 mmol/liter at 15.8 g/m2/day, and 0.99 ± 0.22 mmol/liter at 20 g/m2/day. Depletion of intracellular polyamines in peripheral blood mononuclear leukocytes was noted during several courses that were associated with profound myelosuppression, but no clear relationships were apparent between the magnitude of polyamine changes and toxicity or between fluctuations in polyamines and the magnitude of mean HMBA C(ss) values. Based on this study, the maximum tolerated and recommended phase II doses for HMBA administered on this schedule were 20 and 15.8 g/m2/d, respectively. The administration of HMBA by a ten-day infusion at the maximum tolerated dose resulted in the delivery of lower daily doses and lower HMBA C(ss) than on the 5-day schedule. The major toxicities differed on these schedules with thrombocytopenia being most prominent on the 10-day schedule and metabolic and CNS toxicities on the 5-day schedule. The administration of HMBA for prolonged periods may be disadvantageous in the treatment of myelodysplastic syndromes since thrombocytopenia and marrow failure are common at presentation; however, the efficacy of the two schedules cannot be assessed from these phase I studies.

Original languageEnglish (US)
Pages (from-to)5788-5795
Number of pages8
JournalCancer Research
Volume47
Issue number21
StatePublished - 1987

Fingerprint

hexamethylene bisacetamide
Pharmacology
Appointments and Schedules
Polyamines
Thrombocytopenia
Platelet Count

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prolonged infusion of hemaxamethylene bisacetamide : A phase I and pharmacological study. / Rowinsky, E. K.; Ettinger, David S; McGuire, W. P.; Noe, D. A.; Grochow, L. B.; Donehower, Ross C.

In: Cancer Research, Vol. 47, No. 21, 1987, p. 5788-5795.

Research output: Contribution to journalArticle

Rowinsky, EK, Ettinger, DS, McGuire, WP, Noe, DA, Grochow, LB & Donehower, RC 1987, 'Prolonged infusion of hemaxamethylene bisacetamide: A phase I and pharmacological study', Cancer Research, vol. 47, no. 21, pp. 5788-5795.
Rowinsky, E. K. ; Ettinger, David S ; McGuire, W. P. ; Noe, D. A. ; Grochow, L. B. ; Donehower, Ross C. / Prolonged infusion of hemaxamethylene bisacetamide : A phase I and pharmacological study. In: Cancer Research. 1987 ; Vol. 47, No. 21. pp. 5788-5795.
@article{7e67b60a9da44653aaa58f118a338eb6,
title = "Prolonged infusion of hemaxamethylene bisacetamide: A phase I and pharmacological study",
abstract = "Hexamethylene bisacetamide (HMBA, NSC 95580), a potent polar-planar differentiating agent in vitro, was studied in a phase I trial as a 10-day continuous infusion administered every 4 weeks. Since preclinical evidence had demonstrated that the duration of HMBA exposure was an important variable in the induction of differentiation, and HMBA steady-state concentrations (C(ss)) achieved during 5-day infusions were minimally effective at inducing in vitro differentiation, this study was conducted to evaluate the feasibility of maintaining HMBA C(ss) for 10 days similar to levels achieved and maintained for 5 days. Twelve patients received 17 evaluable courses at three dose levels, 12, 15.8, and 20 g/m2/day. Platelet toxicity limited further dose escalation. Mean nadir and percentage of decrement in platelet counts were 175,000/μl and 66{\%}, and 43,500/μl and 83{\%}, at 15.8 and 20 g/m2/day, respectively. In this 10-day study, the percentage of decrement of platelet counts was linearly related to mean HMBA C(ss) and to the area under the plasma concentration versus time curve (AUC). However, when combined platelet and pharmacological data from both 5- and 10-day studies were analyzed, it was apparent that the duration of HMBA exposure was an additional significant variable in predicting the magnitude of thrombocytopenia. Renal and metabolic toxicities that precluded dose escalation in previous 5-day trials of HMBA were mild and insignificant in this study. Mean HMBA C(ss) 0.65 ± 0.09 mmol/liter at 15.8 g/m2/day, and 0.99 ± 0.22 mmol/liter at 20 g/m2/day. Depletion of intracellular polyamines in peripheral blood mononuclear leukocytes was noted during several courses that were associated with profound myelosuppression, but no clear relationships were apparent between the magnitude of polyamine changes and toxicity or between fluctuations in polyamines and the magnitude of mean HMBA C(ss) values. Based on this study, the maximum tolerated and recommended phase II doses for HMBA administered on this schedule were 20 and 15.8 g/m2/d, respectively. The administration of HMBA by a ten-day infusion at the maximum tolerated dose resulted in the delivery of lower daily doses and lower HMBA C(ss) than on the 5-day schedule. The major toxicities differed on these schedules with thrombocytopenia being most prominent on the 10-day schedule and metabolic and CNS toxicities on the 5-day schedule. The administration of HMBA for prolonged periods may be disadvantageous in the treatment of myelodysplastic syndromes since thrombocytopenia and marrow failure are common at presentation; however, the efficacy of the two schedules cannot be assessed from these phase I studies.",
author = "Rowinsky, {E. K.} and Ettinger, {David S} and McGuire, {W. P.} and Noe, {D. A.} and Grochow, {L. B.} and Donehower, {Ross C}",
year = "1987",
language = "English (US)",
volume = "47",
pages = "5788--5795",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Prolonged infusion of hemaxamethylene bisacetamide

T2 - A phase I and pharmacological study

AU - Rowinsky, E. K.

AU - Ettinger, David S

AU - McGuire, W. P.

AU - Noe, D. A.

AU - Grochow, L. B.

AU - Donehower, Ross C

PY - 1987

Y1 - 1987

N2 - Hexamethylene bisacetamide (HMBA, NSC 95580), a potent polar-planar differentiating agent in vitro, was studied in a phase I trial as a 10-day continuous infusion administered every 4 weeks. Since preclinical evidence had demonstrated that the duration of HMBA exposure was an important variable in the induction of differentiation, and HMBA steady-state concentrations (C(ss)) achieved during 5-day infusions were minimally effective at inducing in vitro differentiation, this study was conducted to evaluate the feasibility of maintaining HMBA C(ss) for 10 days similar to levels achieved and maintained for 5 days. Twelve patients received 17 evaluable courses at three dose levels, 12, 15.8, and 20 g/m2/day. Platelet toxicity limited further dose escalation. Mean nadir and percentage of decrement in platelet counts were 175,000/μl and 66%, and 43,500/μl and 83%, at 15.8 and 20 g/m2/day, respectively. In this 10-day study, the percentage of decrement of platelet counts was linearly related to mean HMBA C(ss) and to the area under the plasma concentration versus time curve (AUC). However, when combined platelet and pharmacological data from both 5- and 10-day studies were analyzed, it was apparent that the duration of HMBA exposure was an additional significant variable in predicting the magnitude of thrombocytopenia. Renal and metabolic toxicities that precluded dose escalation in previous 5-day trials of HMBA were mild and insignificant in this study. Mean HMBA C(ss) 0.65 ± 0.09 mmol/liter at 15.8 g/m2/day, and 0.99 ± 0.22 mmol/liter at 20 g/m2/day. Depletion of intracellular polyamines in peripheral blood mononuclear leukocytes was noted during several courses that were associated with profound myelosuppression, but no clear relationships were apparent between the magnitude of polyamine changes and toxicity or between fluctuations in polyamines and the magnitude of mean HMBA C(ss) values. Based on this study, the maximum tolerated and recommended phase II doses for HMBA administered on this schedule were 20 and 15.8 g/m2/d, respectively. The administration of HMBA by a ten-day infusion at the maximum tolerated dose resulted in the delivery of lower daily doses and lower HMBA C(ss) than on the 5-day schedule. The major toxicities differed on these schedules with thrombocytopenia being most prominent on the 10-day schedule and metabolic and CNS toxicities on the 5-day schedule. The administration of HMBA for prolonged periods may be disadvantageous in the treatment of myelodysplastic syndromes since thrombocytopenia and marrow failure are common at presentation; however, the efficacy of the two schedules cannot be assessed from these phase I studies.

AB - Hexamethylene bisacetamide (HMBA, NSC 95580), a potent polar-planar differentiating agent in vitro, was studied in a phase I trial as a 10-day continuous infusion administered every 4 weeks. Since preclinical evidence had demonstrated that the duration of HMBA exposure was an important variable in the induction of differentiation, and HMBA steady-state concentrations (C(ss)) achieved during 5-day infusions were minimally effective at inducing in vitro differentiation, this study was conducted to evaluate the feasibility of maintaining HMBA C(ss) for 10 days similar to levels achieved and maintained for 5 days. Twelve patients received 17 evaluable courses at three dose levels, 12, 15.8, and 20 g/m2/day. Platelet toxicity limited further dose escalation. Mean nadir and percentage of decrement in platelet counts were 175,000/μl and 66%, and 43,500/μl and 83%, at 15.8 and 20 g/m2/day, respectively. In this 10-day study, the percentage of decrement of platelet counts was linearly related to mean HMBA C(ss) and to the area under the plasma concentration versus time curve (AUC). However, when combined platelet and pharmacological data from both 5- and 10-day studies were analyzed, it was apparent that the duration of HMBA exposure was an additional significant variable in predicting the magnitude of thrombocytopenia. Renal and metabolic toxicities that precluded dose escalation in previous 5-day trials of HMBA were mild and insignificant in this study. Mean HMBA C(ss) 0.65 ± 0.09 mmol/liter at 15.8 g/m2/day, and 0.99 ± 0.22 mmol/liter at 20 g/m2/day. Depletion of intracellular polyamines in peripheral blood mononuclear leukocytes was noted during several courses that were associated with profound myelosuppression, but no clear relationships were apparent between the magnitude of polyamine changes and toxicity or between fluctuations in polyamines and the magnitude of mean HMBA C(ss) values. Based on this study, the maximum tolerated and recommended phase II doses for HMBA administered on this schedule were 20 and 15.8 g/m2/d, respectively. The administration of HMBA by a ten-day infusion at the maximum tolerated dose resulted in the delivery of lower daily doses and lower HMBA C(ss) than on the 5-day schedule. The major toxicities differed on these schedules with thrombocytopenia being most prominent on the 10-day schedule and metabolic and CNS toxicities on the 5-day schedule. The administration of HMBA for prolonged periods may be disadvantageous in the treatment of myelodysplastic syndromes since thrombocytopenia and marrow failure are common at presentation; however, the efficacy of the two schedules cannot be assessed from these phase I studies.

UR - http://www.scopus.com/inward/record.url?scp=0023526090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023526090&partnerID=8YFLogxK

M3 - Article

C2 - 3664482

AN - SCOPUS:0023526090

VL - 47

SP - 5788

EP - 5795

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -